Spectral Medical (TSX:EDT) ROE %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:EDT Spectral Medical Inc TSX:EDT
11 GF Score
Price C$1.36
GF Value C$0.92
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Spectral Medical ROE %?

Spectral Medical TSX:EDT +2.26% 11 ROE % is 0.00% as of Mar. 2026. GuruFocus rates TSX:EDT with a GF Score™ of 11/100 and a GF Value™ of C$0.92 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 499999.5% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Spectral Medical's annualized net income for the quarter that ended in Mar. 2026 was C$-11.75 Mil. Spectral Medical's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was C$-70.25 Mil. Therefore, Spectral Medical's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Spectral Medical's ROE % or its related term are showing as below:

TSX:EDT's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.32
* Ranked among companies with meaningful ROE % only.

Spectral Medical  (TSX:EDT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-11.752/-70.245
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11.752 / 3.564)*(3.564 / 5.3385)*(5.3385 / -70.245)
=Net Margin %*Asset Turnover*Equity Multiplier
=-329.74 %*0.6676*N/A
=ROA %*Equity Multiplier
=-220.13 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-11.752/-70.245
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-11.752 / -11.74) * (-11.74 / 0.288) * (0.288 / 3.564) * (3.564 / 5.3385) * (5.3385 / -70.245)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.001 * -40.7639 * 8.08 % * 0.6676 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Spectral Medical ROE % Related Terms


Spectral Medical ROE % Historical Data

* Premium members only.

The historical data trend for Spectral Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spectral Medical ROE % Chart

Spectral Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -514.65 -1,475.60 0.00 0.00 0.00

Spectral Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSX:EDT vs TMO, DHR, IDXX: ROE % Comparison

For the Diagnostics & Research subindustry, Spectral Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral Medical ROE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Spectral Medical's ROE % falls into.


TSX:EDT
11GF Score
Spectral Medical Inc TSX:EDT
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spectral Medical ROE % Calculation

Spectral Medical's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-47.692/( (-27.545+-69.722)/ 2 )
=-47.692/-48.6335
=N/A %

Spectral Medical's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-11.752/( (-69.722+-70.768)/ 2 )
=-11.752/-70.245
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Spectral Medical (TSX:EDT) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #999999 out of 200 companies in the Medical Diagnostics & Research industry.
Is Spectral Medical's ROE % too high?
Spectral Medical's current ROE % is 0.00%. Based on the distribution chart, Spectral Medical ranks #999999 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #999999 out of 200 companies for ROE %. This places Spectral Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Spectral Medical and its competitors. Spectral Medical's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (TSX:EDT) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.92, compared to a current price of C$1.36 — trading 47.8% above its estimated fair value. The current ROE % is 0.00%. Spectral Medical's overall GF Score™ is 11/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Spectral Medical (TSX:EDT), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spectral Medical (TSX:EDT) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of C$1.36 is trading 47.8% above its estimated GF Value™ of C$0.92. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for TSX:EDT:

  • ROE %: 0.00%
  • GF Value™: C$0.92 vs. price of C$1.36 (47.8% above fair value)
  • GF Score™: 11/100 with 9 warning signs

No single metric tells the full story. See the TSX:EDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spectral Medical Business Description

Other Exchanges EDTXF:USASD4:Germany
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
11GF Score

Get the complete analysis for TSX:EDT

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.36
Price
C$0.92
GF Value